Retraction
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE
Paper Information
Record ID:
24119
Author(s):
Journal:
Publication Date:
December 15, 2017
Retraction Date:
August 21, 2020
(5.3 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- The Royal Marsden NHS Foundation Trust, London
- Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom
- Centro de Referência da Saúde da Mulher
- Hospital Israelita Albert Einstein, São Paulo, Brazil
- Seoul National University College of Medicine, Seoul
- National Cancer Center, Gyeonggi-do, Korea
- Regional Oncology Dispensary, Arkhangelsk
- N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria
- University of Southern California, Los Angeles, CA
- Aichi Cancer Center Hospital, Aichi, Japan
- Novartis Pharma AG, Basel, Switzerland
- Northwestern University, Chicago, IL
Countries:
Article Type:
Publisher:
American Society of Clinical Oncology
Open Access:
No
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1200/JCO.20.02029Additional Notes:
see also: https://ascopubs.org/doi/abs/10.1200/JCO.20.01894;
Citations (157)
157
Total Citations109
Post-Retraction(69.4%)
47
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
28
Within 1 year
60
After 2+ years
1678
Days since retraction (latest)
Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategies
Chao Liu, Lisha Sun, Nan Niu et al. (17 authors)
Signal Transduction and Targeted Therapy
Open Access
Published: Mar 2025
3 citations
3 citations
1678 days after retraction
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
John H. Strickler, Tanios Bekaii‐Saab, Andrea Cercek et al. (13 authors)
Future Oncology
Open Access
Published: Dec 2024
1 citation
1 citation
1588 days after retraction
Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
Jianli Zhao, Yunfang Yu, Wei Ren et al. (21 authors)
MedComm
Open Access
Published: Dec 2024
2 citations
2 citations
1582 days after retraction
Updates in Treatment of HER2-positive Metastatic Breast Cancer
A. Avelino, Soumya Pulipati, Kevin T Jamouss et al. (4 authors)
Current Treatment Options in Oncology
Published: Nov 2024
3 citations
3 citations
1541 days after retraction
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
Guilherme Nader Marta, Christian F. Singer, Dominik Hlauschek et al. (21 authors)
Breast Cancer Research
Open Access
Published: Oct 2024
1 citation
1 citation
1508 days after retraction
Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study
Ran Ran, Shidi Zhao, Yan Zhou et al. (10 authors)
BMC Cancer
Open Access
Published: Sep 2024
3 citations
3 citations
1501 days after retraction
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Adrienne G. Waks, Olga Martínez‐Sáez, Paolo Tarantino et al. (8 authors)
Nature Reviews Clinical Oncology
Published: Sep 2024
7 citations
7 citations
1484 days after retraction
Predictors of pathological complete response to neoadjuvant treatment in invasive breast cancer with different human epidermal growth factor receptor 2 (HER2) subcategories
Bo Sun, Yanbo Li, Jiahui Wang et al. (5 authors)
Quantitative Imaging in Medicine and Surgery
Open Access
Published: Aug 2024
1462 days after retraction
Tocopherol-human serum albumin nanoparticles enhance lapatinib delivery and overcome doxorubicin resistance in breast cancer
Milan Paul, Sneha Das, Balaram Ghosh et al. (4 authors)
Nanomedicine
Published: Jul 2024
2 citations
2 citations
1411 days after retraction
Elemene Injection Overcomes Paclitaxel Resistance in Breast Cancer through AR/RUNX1 Signal: Network Pharmacology and Experimental Validation
Xidong Gu, Leilai Xu, Yuanyuan Fu et al. (9 authors)
Current Pharmaceutical Design
Open Access
Published: Jun 2024
1405 days after retraction
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer
Oğuzcan Kınıkoğlu, Hatice Odabaş, Yunus Emre Altıntaş et al. (14 authors)
Medicina
Open Access
Published: Jun 2024
1386 days after retraction
Twenty-five years with HER2 targeted therapy
Jan Trøst Jørgensen
Annals of Translational Medicine
Open Access
Published: Jun 2024
5 citations
5 citations
1380 days after retraction
A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer
Kerigo Ndirangu, Rachel Goldgrub, Vanita Tongbram et al. (7 authors)
Journal of Comparative Effectiveness Research
Open Access
Published: May 2024
1377 days after retraction
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
Sherko Kuemmel, Catherine Harper‐Wynne, Yeon Hee Park et al. (15 authors)
BMC Cancer
Open Access
Published: May 2024
4 citations
4 citations
1372 days after retraction
Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis
Agustín Ciapponi, Ariel Bardach, Carla Colaci et al. (7 authors)
Revista Peruana de Medicina Experimental y Salud Pública
Open Access
Published: May 2024
1 citation
1 citation
1356 days after retraction
Mexican breast cancer consensus. Management of advanced breast cancer
Guadalupe Cervantes-Sánchez, Tania Hernández-Barragán, Fernando Aldaco-Sarvide et al. (21 authors)
Gaceta Mexicana de Oncología
Open Access
Published: Apr 2024
1343 days after retraction
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
Chiara Tommasi, Giulia Airò, Fabiana Pratticò et al. (15 authors)
Journal of Clinical Medicine
Open Access
Published: Mar 2024
8 citations
8 citations
1311 days after retraction
Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care
Rudolf Weide, Stefan Feiten, C Wassmann et al. (8 authors)
Cancers
Open Access
Published: Mar 2024
3 citations
3 citations
1309 days after retraction
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Lisa A. de Jong et al. (5 authors)
PharmacoEconomics - Open
Open Access
Published: Mar 2024
2 citations
2 citations
1302 days after retraction
Consenso mexicano de cáncer mamario. Manejo del cáncer de mama avanzado
Guadalupe Cervantes-Sánchez, Tania Hernández-Barragán, Fernando Aldaco-Sarvide et al. (21 authors)
Gaceta Mexicana de Oncología
Open Access
Published: Mar 2024
1299 days after retraction
Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA)
Firas Kreidieh, Jennifer L. McQuade
American Heart Journal Plus Cardiology Research and Practice
Open Access
Published: Mar 2024
7 citations
7 citations
1288 days after retraction
HER2-targeted therapies in cancer: a systematic review
Kunrui Zhu, Xinyi Yang, Hebei Tai et al. (6 authors)
Biomarker Research
Open Access
Published: Feb 2024
48 citations
48 citations
1260 days after retraction
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Antonio Marra, Sarat Chandarlapaty, Shanu Modi
Nature Reviews Clinical Oncology
Published: Jan 2024
54 citations
54 citations
1235 days after retraction
Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer
Kena Sun, Xiao‐Jia Wang, Huanping Zhang et al. (5 authors)
Cancer Control
Open Access
Published: Jan 2024
3 citations
3 citations
1228 days after retraction
Systemic Therapies for HER2-Positive Advanced Breast Cancer
Vasileios Angelis, Alicia Okines
Cancers
Open Access
Published: Dec 2023
5 citations
5 citations
1216 days after retraction
Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan
Bo-Fang Chen, Yi‐Fang Tsai, Pei‐Ju Lien et al. (12 authors)
Breast Cancer
Open Access
Published: Dec 2023
1205 days after retraction
Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China
Yujing Tan, Hanfang Jiang, Fei Ma et al. (10 authors)
Thoracic Cancer
Open Access
Published: Nov 2023
2 citations
2 citations
1173 days after retraction
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Malwina Stanowicka-Grada, Elżbieta Senkus
Current Treatment Options in Oncology
Open Access
Published: Oct 2023
25 citations
25 citations
1160 days after retraction
Neratinib for HER2-positive breast cancer with an overlooked option
Liting Guo, Weiwei Shao, Chenfei Zhou et al. (10 authors)
Molecular Medicine
Open Access
Published: Oct 2023
25 citations
25 citations
1141 days after retraction
Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
X W Wu, Yong-Kang Qian, Hua‐Ling Chen et al. (5 authors)
Current Oncology
Open Access
Published: Sep 2023
1120 days after retraction
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Rupert Bartsch, Gabriel Rinnerthaler, Edgar Petru et al. (8 authors)
Wiener klinische Wochenschrift
Open Access
Published: Sep 2023
1 citation
1 citation
1113 days after retraction
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in <i>ERBB2</i>-Positive Metastatic Breast Cancer
Jens Huober, Patrik Weder, Karin Ribi et al. (86 authors)
JAMA Oncology
Open Access
Published: Aug 2023
4 citations
4 citations
1084 days after retraction
Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
Man Yang, Jiale Sun, Liqiong Liu et al. (7 authors)
Scientific Reports
Open Access
Published: Jul 2023
11 citations
11 citations
1074 days after retraction
Effects of clinical treatment decisions on long-term survival outcomes of locally advanced breast cancer with different molecular subtypes based on the SEER database
Qian Fang, Haoyuan Shen, Chunyan Deng et al. (11 authors)
Research Square (Research Square)
Open Access
Published: Jul 2023
1055 days after retraction
Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers
Xiaoxue Wu, Shuting Huang, Weiling He et al. (4 authors)
International Immunopharmacology
Published: Jul 2023
12 citations
12 citations
1053 days after retraction
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
Zhe-Yu Hu, Min Yan, Huihua Xiong et al. (14 authors)
BMC Medicine
Open Access
Published: Jun 2023
11 citations
11 citations
1039 days after retraction
Analysis of the metastatic mechanism and progress in the treatment of breast cancer liver metastasis: a narrative review
Guanmo Liu, Fan Yang, Lu Gao et al. (7 authors)
Translational Cancer Research
Open Access
Published: Jun 2023
2 citations
2 citations
1014 days after retraction
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
Mark D. Pegram, Christian Jackisch, Stephen Johnston
npj Breast Cancer
Open Access
Published: May 2023
70 citations
70 citations
1013 days after retraction
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
Aya Abunada, Zaid Sirhan, Anita Thyagarajan et al. (4 authors)
World Journal of Clinical Oncology
Open Access
Published: May 2023
4 citations
4 citations
1001 days after retraction
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study
Alessandro Rossi, Giacomo Aimar, Marco Audisio et al. (20 authors)
European Journal of Cancer
Published: May 2023
12 citations
12 citations
997 days after retraction
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Seock‐Ah Im, Alessandra Gennari, Y.H. Park et al. (31 authors)
ESMO Open
Open Access
Published: May 2023
31 citations
31 citations
993 days after retraction
Targeting the formation of estrogens for treatment of hormone dependent diseases–current status
Tea Lanišnik Rižner, Andrea Romano
Frontiers in Pharmacology
Open Access
Published: Apr 2023
14 citations
14 citations
980 days after retraction
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
Maria Hinterberger, Kathrin Endt, Barbara Bathke et al. (16 authors)
Scientific Reports
Open Access
Published: Mar 2023
4 citations
4 citations
951 days after retraction
Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1
Jankiben Patel, Bipika Banjara, Afia Ohemeng et al. (7 authors)
Nutrients
Open Access
Published: Mar 2023
5 citations
5 citations
949 days after retraction
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
Ismail Essâdi, Zineb Benbrahim, Mohamed Kaakoua et al. (6 authors)
Cancers
Open Access
Published: Mar 2023
19 citations
19 citations
934 days after retraction
Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer
Nidhi Singh, Kolimi Prashanth Reddy, Priyanka Das et al. (5 authors)
Journal of Drug Delivery Science and Technology
Published: Mar 2023
7 citations
7 citations
924 days after retraction
Developing SHP2-based combination therapy for KRAS-amplified cancer
Tianxia Li, Osamu Kikuchi, Jin Zhou et al. (13 authors)
JCI Insight
Open Access
Published: Feb 2023
8 citations
8 citations
900 days after retraction
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini et al. (9 authors)
npj Breast Cancer
Open Access
Published: Feb 2023
6 citations
6 citations
897 days after retraction
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis
Grazia Arpino, Juan de la Haba-Rodríguez, Jean-Marc Ferrero et al. (10 authors)
Clinical Cancer Research
Open Access
Published: Jan 2023
27 citations
27 citations
892 days after retraction
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer
Matthew Loft, Sheau Wen Lok, Richard de Boer et al. (16 authors)
Breast Cancer Research and Treatment
Published: Jan 2023
8 citations
8 citations
871 days after retraction
Quick Stats
Total Citations:
157
Years Since Retraction:
5.3 years
Open Access:
No
Last Checked:
Jul 24, 2025